Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Clinical Efficacy of Jing Si Herbal Tea Liquid Packet to Treat Patients With Interstitial Cystitis/Bladder Pain Syndrome

3. November 2026 aktualisiert von: Wan Ru Yu, Hualien Tzu Chi General Hospital

Jing Si Herbal Tea Liquid Packet Combined Bladder Treatment or Only Bladder Treatment, and to Evaluate the Effect of the Jing Si Herbal Tea Liquid Packet Intervention of IC/BPS

Introduction: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a disease of unknown etiology, with clinical characteristics of bladder pain, frequency, urgency, and nocturia. There has been no effective and durable medication to cure this disease. Current research has revealed that chronic bladder wall inflammation and bladder mucosal denudation are the fundamental pathology for clinical symptoms. Using Jing Si Herbal Tea liquid packets may have a therapeutic effect in patients with refractory IC/BPS.

Aim: To investigate the effect of Jing Si Herbal Tea liquid packet intervention added to urological therapy for patients with refractory IC/BPS.

Materials and Methods: This study will enroll patients with IC/BPS who are refractory to various conventional treatments after cystoscopic hydrodistention, antimuscarinic, and painkiller treatments. These patients plan to receive further intravesical IC therapy, such as intravesical hyaluronic acid (HA) instillation, intravesical botulinum toxin A (Botox) injection, intravesical platelet-rich plasma (PRP) injection, or low-energy shock wave (LESW) therapy. The patients will be randomly assigned to receive intravesical IC therapy and placebo (control group) or concomitant IC treatment with Jing Si Herbal Tea liquid packet TID (treatment group) for 3 months. The voiding diary, ICSI, ICPI, VAS, PPBC, GRA, Qmax, Vol, and PVR are also assessed at baseline and at 4, 12, and 20 weeks after treatment. The primary endpoint of this study is the improvement of GRA by 2 points at 12 weeks after treatment.

Assessment: The patients will be investigated using the voiding diary (for frequency of nocturia episodes per day), ICSI, IC problem index (ICPI), Numerical Rating Scale (NRS) of pain, patient perception of bladder condition (PPBC), global response assessment (GRA), maximal flow rate (Qmax), voided volume (Vol), and post-void residual urine (PVR) volume measurement at baseline and after treatment. Urine samples will also be obtained for determination of urinary biomarkers at baseline and after different therapies.

Studienübersicht

Detaillierte Beschreibung

Introduction: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a disease of unknown etiology, with clinical characteristics of bladder pain, frequency, urgency, and nocturia. There has been no effective and durable medication to cure this disease. Patients with IC/BPS have increased anxiety, depression, loss of social relationships, and a high suicide rate due to intolerable symptoms. Current research has revealed that chronic bladder wall inflammation and bladder mucosal denudation are the fundamental pathology for clinical symptoms. After medical treatment or intravesical therapy, urinary inflammatory biomarkers may decrease, and this reduction is associated with clinical symptom improvement. Jing-Si Herbal Tea is a traditional Chinese medicine product that has been shown to have potential effects on autonomic nervous system modulation, immunomodulation, and antioxidant activity. Using Jing-Si-Herbal-Tea may have a therapeutic effect in patients with refractory IC/BPS.

Material and Methods: This study will enroll patients with IC/BPS who are refractory to various conventional treatments (an interstitial cystitis symptom index (ICSI) >12 after cystoscopic hydrodistention, antimuscarinic, and painkiller treatments). These patients plan to receive further intravesical IC therapy, such as intravesical hyaluronic acid (HA) instillation, intravesical botulinum toxin A (Botox) injection, intravesical platelet-rich plasma (PRP) injection, or low-energy shock wave (LESW) therapy. The patients will be investigated for the voiding diary (for frequency and nocturia episodes per day), ICSI, IC problem index (ICPI), Numerical Rating Scale (NRS) of pain, patient perception of bladder condition (PPBC), global response assessment (GRA), maximal flow rate (Qmax), voided volume (Vol), and post-void residual urine (PVR) volume measurement at baseline and after treatment. Urine samples will also be obtained for urinary biomarker determination at baseline and after different therapies. The patients will be randomly assigned to receive intravesical IC therapy and placebo (control group) or concomitant IC treatment with Jing-Si-Herbal-Tea TID (treatment group) for 3 months. The voiding diary, ICSI, ICPI, VAS, PPBC, GRA, Qmax, Vol, and PVR are also assessed at baseline and at 4, 8, and 12 weeks after treatment. The primary endpoint of this study is the improvement of GRA by 2 points at 12 weeks after treatment. The urinary biomarker levels will also be compared before baseline and after treatment. Secondary endpoints include ICSI and ICPI, assessed by self-report of IC/BPS severity and NRS for pain severity; the range of ICSI is 0 to 20 points, and the ICPI total score is 0 to 16 points. Bladder pain was assessed using a self-rated 11-point NRS for severity.

Expected results: The investigators expect IC/BPS patients in the treatment group (combined IC treatment and Jing-Si-Herbal-Tea treatment) to have significantly greater improvement in GRA after 12 weeks of treatment. The investigators also expect that improvement in bladder pain (as measured by NRS) might be the most effective indicator of treatment outcome.

Studientyp

Interventionell

Einschreibung (Geschätzt)

80

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Hualien City, Taiwan, 970
        • Hualien Tzu Chi General Hospital, Tzu Chi Medical Foundation

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

20 Jahre bis 84 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • This study is expected to select patients with IC (non-ulcer type, Glomerulation >1, interstitial cystitis symptom index (ICSI≧12 points) in the urology outpatient clinic, and use anticholinergic drugs and pain medication treatment. The symptoms have not improved significantly (ICSI≧12). Patients will be asked about their willingness before being selected to confirm that they are willing to accept this clinical trial, and they can be included in this clinical trial after completing the entire course of the treatment test.

Exclusion Criteria:

  1. non-IC/BPS patients

  2. psychological disease was diagnosed

  3. non-NIDDK criteria (Hunner's ulcer type)

  4. Under-primary or illiterate respondents

  5. patients with severe cardiopulmonary disease and such as congestive heart failure, arrhythmia, poorly controlled hypertension, not able to receive regular follow up

  6. Patients with bladder outlet obstruction on enrollment

  7. Patients with post-void residual > 150ml

  8. Patients with an uncontrolled confirmed diagnosis of acute urinary tract infection

  9. Patients have laboratory abnormalities at screening including:

    ALT> 3 x upper limit of normal range AST> 3 x upper limit of normal range Patients have abnormal serum creatinine level >2 x upper limit of normal range

  10. Patients who cannot used urinary catheter to treat.

  11. Female patients who are pregnant, lactating, or childbearing potential without contraception.

  12. Patients with any other serious disease considered by the investigator not in the condition to enter the trial

  13. Patients cannot record the voiding diary

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Versorgungsforschung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Jing Si Herbal Tea liquid packet to treat patients with Interstitial Cystitis/Bladder Pain syndrome

Patients who meet all eligibility requirements for entry into the study will be randomized into combined bladder treatment or only bladder treatment

The patients will be randomly assigned to receive intravesical IC therapy and placebo (control group) or concomitant IC treatment with Jing Si Herbal Tea liquid packet TID (treatment group) for 3 months. The voiding diary, ICSI, ICPI, VAS, PPBC, GRA, Qmax, Vol, and PVR are also investigated at baseline and after treatment, at 4 weeks, 8 weeks, 12 weeks, and 20 weeks after the treatment. The primary endpoint of this study is the improvement of GRA by 2 points at 12 weeks after treatment. The urinary biomarker levels will also be compared before baseline and after treatment.

Andere Namen:
  • Jing Si Herbal Tea liquid packet placebo
Placebo-Komparator: Jing Si Herbal Tea liquid packet placebo

Jing Si Herbal Tea liquid packet

The patients will be randomly assigned to receive intravesical IC therapy and placebo (control group) or concomitant IC treatment with Jing Si Herbal Tea liquid packet TID (treatment group) for 3 months. The voiding diary, ICSI, ICPI, VAS, PPBC, GRA, Qmax, Vol, and PVR are also investigated at baseline and after treatment, at 4 weeks, 8 weeks, 12 weeks, and 20 weeks after the treatment. The primary endpoint of this study is the improvement of GRA by 2 points at 12 weeks after treatment. The urinary biomarker levels will also be compared before baseline and after treatment.

Andere Namen:
  • Jing Si Herbal Tea liquid packet placebo

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Global Response Assessment (GRA) at Week 12
Zeitfenster: Week 12

The Global Response Assessment (GRA) evaluates patient-reported overall changes in bladder symptoms following treatment. Higher scores indicate greater perceived improvement.

Week 12

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Interstitial Cystitis Symptom Index (ICSI)
Zeitfenster: Baseline and Week 12

The Interstitial Cystitis Symptom Index (ICSI) assesses the severity of urinary frequency, urgency, nocturia, and bladder-related pain. Total scores range from 0 to 20, with higher scores indicating more severe symptoms. Change from baseline will be assessed.

Baseline and Week 12
Change in Interstitial Cystitis Problem Index (ICPI)
Zeitfenster: Baseline and Week 12

The Interstitial Cystitis Problem Index (ICPI) measures the degree of bother associated with urinary symptoms. Total scores range from 0 to 16, with higher scores indicating greater symptom-related problems. Change from baseline will be assessed.

Baseline and Week 12
Change in Bladder Pain Intensity
Zeitfenster: Baseline and Week 12

Bladder pain intensity is assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Change from baseline will be assessed.

Baseline and Week 12

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Hann Chorng Kuo, M.D., Buddhist Tzu Chi Medical Foundation Hualien Tzu Chi Hospital

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

31. August 2026

Primärer Abschluss (Tatsächlich)

31. August 2026

Studienabschluss (Geschätzt)

1. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

8. Februar 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

3. November 2026

Zuerst gepostet (Tatsächlich)

10. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

10. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

3. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • IRB112-149-A
  • IRB112-149-A (Andere Zuschuss-/Finanzierungsnummer: Buddhist Tzu Chi General Hospital, Hualien)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren